This is a multiple dose study of the safety and efficacy of MK-2748 to be done in 2 Parts.
Part I will enroll genotype 1 (GT1) hepatitis C virus (HCV)-infected participants and Part II
will enroll genotype 3 (GT3) HCV-infected participants. Both Parts may run concurrently or
may be staggered.